Metro International Biotech is a privately-owned clinical-stage pharmaceutical company that has established the most comprehensive portfolio of proprietary NAD+ precursors in the world.

NAD+ levels have been shown to decline as humans age and increasing NAD+ to preserve health and normal metabolism is believed to have broad pharmaceutical potential. Metro International Biotech has assembled a team of industry-leading scientists to drive its lead compound, MIB-626, through clinical development and fuel the Company’s robust R&D engine, building a library of next-generation analogs with tissue-selective NAD+ increasing properties.


Our Mission:

To enable longer, healthier lives.

Screenshot 2019-01-04 14.50.48.png


Since its founding, Metro International Biotech has built a world class, highly collaborative team of leading NAD+ experts, with extensive clinical and corporate experience, as well as in related fields such as metabolic pathways, drug development and manufacturing, molecular biology, isotopic labeling and nucleoside chemistry.




Edward Schulak, Chairman

David J. Livingston, MBA, Ph.D., Chief Scientific Officer

Kyle Meetze, MBA, Chief Business Officer

Michael Willis, Ph.D., JD, Corporate Counsel





David Sinclair, Ph.D., SAB Chair and Co-Founder

Anthony Sauve, Ph.D., Co-Founder

Rajendra Apte, M.D., Ph.D., Co-Founder

James Ellis, Ph.D., SAB Member

Lindsay Wu, Ph.D., SAB Member

Johan Auwerx, M.D., Ph.D., SAB Member

Nick Lane, Ph.D., SAB Member

Neil Flanzraich, JD., SAB Member


What We've Achieved

  • Manufacturing a naturally occurring proprietary human clinical grade NAD+ enhancer

  • Designed and synthesized over 100 novel NAD+ enhancers, screened for optimal therapeutic properties

  • Gathered robust preclinical data supporting the broad therapeutic potential of modulating NAD+

  • Developed solid oral dosage formulations of MIB-626, with scalable manufacturing capabilities

  • Protected extensive IP portfolio, with 21 patent families and in-house proprietary R&D

  • Ongoing Phase 1 trials at a leading hospital in Boston